Identifying therapies for diseases such as addiction, PTSD, depression, and anxiety.

Millions of Americans suffer from depression, anxiety, addiction, post-traumatic stress disorder (PTSD), Alzheimer’s, and other mental health conditions.  Unfortunately, too often the current treatment approaches have limited effectiveness resulting in lifetimes of unbearable symptoms, lowered quality of life, and high rates of mortality.

However, psychedelic compounds present a new opportunity for addressing these treatment-resistant conditions.  Based on early studies, psilocybin, the active ingredient of “magic mushrooms”, has positive and long-lasting effects on some of the most debilitating and chronic medical conditions, including addiction, anxiety, and major depression.  Similarly, in a study of MDMA-assisted psychotherapy, approximately two-thirds of patients with treatment-resistant PTSD no longer met the diagnostic criteria for PTSD at the one-year follow-up.

Research on these psychedelic compounds has been postponed for decades while millions of Americans have profoundly suffered.  It’s time to unlock the potential of psychedelic medicine and improve the lives of patients and their families.

Currently, the Foundation is one of the largest private funders of psychedelic research in the country as we push to fund ground-breaking projects and bring hope to patients with these devastating conditions.


Given to Psychedelic Projects

Real Sports with Bryant Gumbel: Psychedelics in Sports | HBO

Psilocybin, love and the meaning of life | Mary Cosimano | TEDxKC

Steven and Alexandra Cohen Foundation Heart Logo

Featured Grantees